DIH Holdings US Stock Price, News & Analysis

DIH (NASDAQ:DHAI) has designated Sheltering Arms Institute, a collaboration with VCU Health, as a DIH Center of Excellence. The institute, located in Richmond, Virginia, utilizes DIH's Total Solution, including Erigo®Pro, Lokomat®Pro, Andago V2.0®, RYSEN, C-Mill VR+, Armeo®Power, and Armeo®Spring to provide personalized rehabilitation care. This partnership strengthens DIH's presence among top-tier healthcare providers and recognizes Sheltering Arms Institute's role in showcasing best practices in rehabilitation robotics. The institute will contribute to developing advanced rehabilitation technologies and implementing them across North America.

DIH (NASDAQ:DHAI) reported Q2 2025 financial results with revenue of $18.2 million, up 39% year-over-year. Device revenue grew 49% to $15.0 million, while service revenue remained flat at $2.7 million. The company saw significant growth in EMEA (72%) and Americas (20%). Gross margin improved to 52.6%, and income before taxes reached $0.1 million.

The company restated Q1 2025 revenue to $17.0 million (30% YoY growth) from previously reported $16.2 million. DIH revised its fiscal year 2025 revenue guidance to $60-67 million. The restatement was due to timing adjustments for two device sales in June 2024.

DIH (NASDAQ:DHAI) has appointed Dietmar Dold as Chief Operating Officer, effective immediately. With over 25 years of operating experience, Dold will lead DIH's multi-group operating strategy, focusing on optimizing manufacturing, sourcing initiatives, and building operations teams. Previously, he served as CEO at Videojet Technologies and held positions at KPMG, Condair Group, Sonova, and Roche Diagnostics. At Air New Zealand, he contributed to tripling the company's value over three years. Dold holds a computer science degree, an Executive MBA, and a Board of Director Diploma from IMD.

DIH Holding US, Inc. (NASDAQ:DHAI) has announced the formation of its Scientific Advisory Board (SAB). The SAB will advise DIH on technical and scientific matters, offer insights into industry trends, provide feedback on product development, and advise on research plans. The board comprises leading scientists and clinicians with expertise in rehabilitation technologies, biomechanics, neuromuscular control, and related fields.

The inaugural SAB members include:

• Paolo Bonato, Ph.D. - Director of Motion Analysis Laboratory at Spaulding Rehabilitation Hospital
• Jonathan Dingwell, Ph.D. - Professor of Kinesiology at Pennsylvania State University
• Alberto Esquenazi, MD - Chief Medical Officer at MossRehab
• Kenneth Meijer, Ph.D. - Professor of Human Movement Sciences at Maastricht University
• Giovanni Morone, MD - Assistant Professor at University of L'Aquila
• David Reinkensmeyer, Ph.D. - Professor at University of California at Irvine
• Robert Riener, Ph.D. - Professor at ETH Zürich
• Melvyn Roerdink, Ph.D. - Associate Professor at Vrije Universiteit Amsterdam

The inaugural meeting took place on September 23rd in Switzerland.

DIH Holding US, Inc. (NASDAQ:DHAI) has appointed Haapsalu Neurological Rehabilitation Center (HNRC) in Estonia as its latest DIH Center of Excellence. HNRC, founded in 1958, is the first such center in the Baltics Region. The center utilizes DIH's advanced robotic rehabilitation technologies, including Hocoma's Lokomat®Pro, Erigo® devices, and Armeo®Spring for comprehensive patient care.

HNRC offers inpatient and outpatient rehabilitation services for children and adults with neurological disorders, combining innovative technologies with clinical expertise. This appointment recognizes HNRC's commitment to integrating cutting-edge solutions into patient care and setting new standards for neurorehabilitation in the region.

DIH Holding US, Inc. (NASDAQ:DHAI) announced financial results for Q1 FY2025 ended June 30, 2024. Key highlights include:

• Revenue of $16.2 million, up 24% year-over-year
• Device revenue of $12.3 million (+18%) and service revenue of $3.5 million (+49%)
• 54% revenue growth in both EMEA and Americas
• Gross Margin improved to 53.5%, up 12 percentage points
• Net loss reduced to $0.6 million, a $2.3 million improvement

DIH reiterated its FY2025 revenue guidance of $74-$77 million, representing 15-20% growth. The company reported strong performance in strategic markets and improved operational efficiency. Cash and cash equivalents totaled $2.7 million as of June 30, 2024.

DIH Holding US, Inc. (NASDAQ:DHAI) reported financial results for fiscal 2024, ending March 31, 2024. Key highlights include:

- Revenue of $64.5 million, up 19% year-over-year
- Device revenue of $51.1 million, up 18%
- Service revenue of $11.1 million, up 20%
- Positive operating cash flow of $5.2 million
- Strategic partnership with B. Temia for exclusive licensing of Keego™ Dermoskeleton in North America

For Q4 2024, revenue decreased 10.2% to $19.4 million due to customer scheduling delays. The company issued $3.3 million in convertible debentures post-fiscal year. For fiscal 2025, DIH projects revenue between $74-77 million, representing 15-20% growth.

DIH announced that Zihlschlacht Rehabilitation Clinic in Switzerland has been appointed as the first DIH Center of Excellence in the country. Established in 1891 and located near Lake Constance, the clinic is renowned for its leadership in treating neurological diseases and pioneering neurorehabilitation efforts. The clinic employs DIH's advanced robotic rehabilitation technologies, including Hocoma's Lokomat®Pro and Andago, and Motek's C-Mill VR+. This recognition highlights Zihlschlacht’s commitment to using innovative technology for neurological care and improving patient outcomes. DIH's Center of Excellence program aims to showcase best practices and support the development of advanced rehabilitation technologies.

DIH Holding has announced a strategic partnership with B-Temia to revolutionize the rehabilitation market by integrating AI-based robotics and smart solutions. The collaboration will incorporate Keeogo Dermoskeleton into DIH's offerings, enabling concurrent therapies for patients in semi-acute and chronic phases. The partnership gives DIH exclusive rights to market Keeogo in Canada, the US, and Mexico, aiming to enhance its product range and industry leadership. DIH plans to validate these innovations in the US market first before global rollout. The partnership seeks to improve patient outcomes through advanced AI and Machine Learning technologies.